Home / Health / New Hope for Childhood Obesity: Drug Shows Promise
New Hope for Childhood Obesity: Drug Shows Promise
19 Nov
Summary
- A weight loss medication has shown effectiveness in children as young as 6.
- Nearly 40% of participants no longer had obesity after 68 weeks.
- Concerns remain about side effects like vomiting and impact on growth.
New research indicates that a weight loss medication may effectively treat obesity in children as young as 6 years old. A phase 3 clinical trial shared by Novo Nordisk demonstrated that its drug, Wegovy, significantly reduced Body Mass Index in most children aged 6 to 11 with obesity.
After 68 weeks, almost 40% of children taking semaglutide, the active ingredient in Wegovy, no longer had obesity. This contrasts sharply with the placebo group, where nearly all patients still had obesity. Wegovy is currently approved by the FDA for children aged 12 and above, but the company plans to apply for a lower age indication.
Physicians express mixed reactions regarding the widespread use of GLP-1s in younger children. Some see it as a preventative measure against severe obesity and related conditions like fatty liver disease and sleep apnea. Dr. Mary Pat Gallagher noted the "remarkable result" and suggested it could consolidate treatment for multiple conditions into one medication.
However, concerns persist about potential side effects. While the study found no new major safety issues, gastrointestinal issues were more common. Vomiting occurred in 70% of the semaglutide group compared to 29% in the placebo group. Diarrhea and nausea were also more frequent in the drug group.
Additionally, a difference in linear growth was observed, with children on semaglutide growing about 1.3 inches less than those on placebo. Experts like Dr. Jade Cobern emphasize the need for more follow-up to understand the long-term impact on growth and body composition. Cobern also highlighted the potential impact of side effects like vomiting on a young child's daily life and schooling.
Despite these concerns, some specialists believe the potential benefits outweigh theoretical risks. Dr. Gallagher stated that the possibility of reduced height would not deter her from prescribing the medication to a child with severe obesity and co-existing health issues. She stressed that childhood obesity is a chronic illness requiring intervention.
Other doctors, while acknowledging the medication as a valuable tool, advocate for its use as part of a broader strategy. Cobern suggested it could be a useful addition for some children with severe obesity when lifestyle interventions fall short, but not as a primary or standalone treatment.